Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00872898 · ClinicalTrials.gov registry record · Phase 2
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT00872898 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 124 participants.
The verdict
NCT00872898, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and efficacy of memantine extended release, as well as its extent of absorption in pediatric patients with autism.
Interventions
- DRUG Placebo
- DRUG Memantine - Extended Release (ER)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00872898
The ClinicalTrials.gov registry entry for NCT00872898 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00872898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00872898 about?
NCT00872898 is a clinical study titled "Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism". The purpose of this study is to investigate the safety and efficacy of memantine extended release, as well as its extent of absorption in pediatric patients with autism.
What is the current status of trial NCT00872898?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2009-04.
What interventions are being tested in trial NCT00872898?
The interventions under investigation include: Placebo (DRUG), Memantine - Extended Release (ER) (DRUG).
Who is sponsoring clinical trial NCT00872898?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.